Evidence map›Paper›PMID 33550636›Full record

Observational studyJournal of inherited metabolic disease2021

Seizure phenotype in CLN3 disease and its relation to other neurologic outcome measures.

Myriam Abdennadher, Sara Inati, Ariane Soldatos, Gina Norato, Eva H Baker, Audrey Thurm, Luca Bartolini, Ruturaj Masvekar, William Theodore, Bibiana Bielekova and 2 more

Open access · bronzeAbstract readObservational Study
In one paragraph

Observational study in Journal of inherited metabolic disease, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.6field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Brain proton MR spectroscopy measurements in CLN3 disease.Molecular genetics and metabolism · 2023
    Article
  6. Molecular syndromology · 2023
    Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 7 institutions in 2 countries.

Myriam AbdennadherNational Institute of Neurological Disorders and Stroke, NIH, Bethesda, Maryland, USA.ORCID 0000-0001-7238-2560
Sara InatiNational Institute of Neurological Disorders and Stroke, NIH, Bethesda, Maryland, USA.
Ariane SoldatosNational Institute of Neurological Disorders and Stroke, NIH, Bethesda, Maryland, USA.
Gina NoratoNational Institute of Neurological Disorders and Stroke, NIH, Bethesda, Maryland, USA.
Eva H BakerRadiology and Imaging Sciences Department, Clinical Center, NIH, Bethesda, Maryland, USA.
Audrey ThurmNational Institute of Mental Health, NIH, Bethesda, Maryland, USA.
Luca BartoliniNational Institute of Neurological Disorders and Stroke, NIH, Bethesda, Maryland, USA.
Ruturaj MasvekarNational Institute of Allergy and Infectious Diseases, NIH, Bethesda, Maryland, USA.
William TheodoreNational Institute of Neurological Disorders and Stroke, NIH, Bethesda, Maryland, USA.
Bibiana BielekovaNational Institute of Allergy and Infectious Diseases, NIH, Bethesda, Maryland, USA.
Forbes D PorterEunice Kennedy Shriver National Institute of Child Health and Human Development, NIH, Bethesda, Maryland, USA.
An N Dang DoEunice Kennedy Shriver National Institute of Child Health and Human Development, NIH, Bethesda, Maryland, USA.
National Institute of Neurological Disorders and Stroke · USEunice Kennedy Shriver National Institute of Child Health and Human Development · USNational Institute of Allergy and Infectious Diseases · USBoston University · USBrown University · USNational Institute of Mental Health · USNational Institutes of Health Clinical Center · US

Funding

Comprehensive multimodal analysis of patients with neuroimmunological diseasesZIAAI001242 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI BIELEKOVA, BIBIANA · 2019 to 2025
$12.9M
Neurodevelopmental and Behavioral Phenotyping ZICMH002961 · NIMH · NATIONAL INSTITUTE OF MENTAL HEALTH · PI THURM, AUDREY · 2017 to 2025
$12.6M
Clinical Investigations of Inborn Errors of MetabolismZIAHD008989 · NICHD · EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT · PI PORTER, FORBES · 2020 to 2025
$5.1M
Intramural NIH HHS ZIA HD008989Intramural NIH HHS ZIC MH002961
6 · The paper itself

Abstract

CLN3 disease is a pediatric neurodegenerative condition wherein seizures are common. The most common disease-causing variant is an ~1-kb deletion in CLN3. We investigated seizure phenotype in relation to genotype and to adaptive behavior, MR spectroscopy and CSF biochemical markers in a CLN3 cohort. We performed seizure phenotyping using clinical history, EEG, and the Unified Batten Disease Rating Scale (UBDRS) seizure score. We assessed correlations of seizure severity with disease severity (UBDRS capability), adaptive behavior composite score (ABC; Vineland-3), glutamate+glutamine+GABA and N-acetylaspartate+N-acetylaspartyl glutamate (MR spectroscopy), and CSF neurofilament light chain (NEFL) levels. In 20 participants, median age was 10.7 years (IQR = 7.8). Eighteen completed baseline EEG; 12 had a 1-year follow-up. Seizures were reported in 14 (8 1-kb deletion homozygotes), with median age at onset of 10.0 (IQR = 6.8). Epileptiform discharges were noted in 15 (9 homozygotes). Bilateral tonic clonic (n = 11) and nonmotor seizures (n = 7) were most common. UBDRS seizure score correlated with age (rp = 0.50; [0.08,0.77]; P = .02), UBDRS capability (rp = -0.57; [-0.81,-0.17]; P = .009) and ABC (rp = -0.66; [-0.85,-0.31]; P = .001) scores, glutamate+glutamine+GABA (rp = -0.54; [-0.80,-0.11]; P = .02) and N-acetylaspartate+N-acetylaspartyl glutamate (rp = -0.54; [-0.80,-0.11]; P = .02), and CSF NEFL (rp = 0.65; [0.29,0.85]; P = .002) levels. After controlling for age, correlations with ABC and CSF NEFL remained significant. In our CLN3 cohort, seizures and epileptiform discharges were frequent and often started by age 10 years without significant difference between genotypes. ABC and CSF NEFL correlate with UBDRS seizure score, reflecting the role of seizures in the neurodegenerative process. Longitudinal evaluations in a larger cohort are needed to confirm these findings.

Indexed as

AdolescentBiomarkersChildChild, PreschoolCohort StudiesElectroencephalographyFemaleHumansMaleMembrane GlycoproteinsMolecular ChaperonesNeuronal Ceroid-LipofuscinosesPhenotypeSeizuresSeverity of Illness IndexBiomarkersCLN3 protein, humanMembrane GlycoproteinsMolecular Chaperonesadaptive behaviorbatten diseaseEEGMRSnatural historyneurofilament light chainUBDRS

Identifiers

PMID33550636
PMCPMC9437865
OpenAlexW3129142592

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.